Browse by Clinical Topic:


Featured CME/CE Content:
 
neuroscienceCME Editors' Picks:



Precision Medicine in Rheumatoid Arthritis: Examining the Evidence for Biomarkers in Diagnosis and Sustaining Remission During De-Escalation

Premiere Date: Wednesday, March 9, 2022

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. PA (aapa)
  6. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Thursday, March 9, 2023

Faculty


Janet Pope, MD, MPH, FRCPCJanet Pope, MD, MPH, FRCPC (Moderator)
Professor of Medicine
Division of Rheumatology
Schulich School of Medicine & Dentistry
Western University
London, Ontario Canada

Allan Gibofsky, MD, JD, MACR, FACP, FCLMAllan Gibofsky, MD, JD, MACR, FACP, FCLM 
Professor of Medicine
Weill Cornell Medicine
Attending Rheumatologist
Co-Director, Clinic for Inflammatory Arthritis
Hospital for Special Surgery
New York, NY

Roy  Fleischmann, MD, MACRRoy  Fleischmann, MD, MACR 
Co-Medical Director Metroplex Clinical Research Center
Clinical Professor of Medicine
University of Texas Southwestern Medical Center
Dallas, TX

Statement of Need

Advances in precision medicine for rheumatoid arthritis (RA) include greater characterization of RA-associated biomarkers that help inform diagnosis, prognosis, and treatment selection. These factors, combined with standard methods of treatment selection that include disease activity and drug characteristics, can improve outcomes in RA. Furthermore, the application of precision medicine to disease-modifying antirheumatic drug (DMARD) de-escalation can help to increase chances of achieving durable, long-term remission, further improving outcomes for individuals with RA.

In this CME Outfitters Live and OnDemand activity, an expert panel will explore and provide practical examples of how biomarkers not only help detect early RA, but are critical to actively monitoring disease progression, gauging DMARD efficacy and patient treatment response, and guiding de-escalation therapy in patients who have achieved remission with DMARDs.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Recognize the role of serologic biomarkers in accurate and timely diagnosis of RA.
  • Apply treatment strategies based on disease activity and serologic biomarkers in patients with RA.
  • Evaluate methods of predicting sustained remission following de-escalation of therapy.

Financial Support

Supported by an educational grant from Bristol Myers Squibb

Target Audience

Rheumatologists, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Enduring

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Pope reports the following financial relationships:

Advisory Boards: AbbVie Inc.; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Frensenius Kabi, Galapagos NV; GlaxoSmithKline; Janssen; Lilly; Novartis; Organon; Pfizer Inc.; Sandoz; UCB; and Viatris

Consultant: AbbVie Inc.; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Celltrion; Emerald Health Pharmaceuticals; Frensenius Kabi; Galapagos NV; GlaxoSmithKline; Janssen; Lilly; Mallinckrodt Pharmaceuticals; Medexus Pharmaceuticals; Mitsubishi Tanabe Pharma; Novartis; Pfizer Inc.; Roche; Sandoz; Samsung; Sobi; and Viatris

Grants/Research Support: Frensenius Kabi; Mallinckrodt Pharmaceuticals; and Seagen

Dr. Gibofsky reports the following financial relationships:

Advisory Boards: AbbVie Inc.; Aurinia Pharmaceuticals Inc.; Biosplice Therapeutics, Inc. (Samumed); Gilead Sciences, Inc.;Lilly; Novartis; and Pfizer Inc.

Consultant: AbbVie Inc.; Acquist Therapeutics, Inc.; Amgen Inc.; Biosplice Therapeutics, Inc. (Samumed); Gilead Sciences, Inc; Janssen Therapeutics; Novartis; Pfizer Inc.

Stock Shareholder: AbbVie Inc.; Johnson & Johnson Services, Inc.; Pfizer Inc.; and Regeneron Pharmaceuticals Inc.

Dr. Fleischmann reports the following financial relationships:

Advisory Board: AbbVie Inc.; Amgen; Bristol Myers Squibb; Galvani; Gilead Sciences, Inc.; GlaxoSmithKline; Lilly; Novartis; and Pfizer Inc.

Consultant: AbbVie Inc.; Amgen; Bristol Myers Squibb; Galvani; Gilead Sciences, Inc.; GlaxoSmithKline; Lilly; Novartis; and Pfizer Inc.

Research Support AbbVie Inc; Amgen; Biosplice; Bristol Myers Squibb; Flexion; Galvani; Gilead Sciences, Inc.; GlaxoSmithKline; Horizon; Lilly; Novartis; Pfizer Inc.; Teva Pharmaceuticals; Viela; Vorso; and UCB

The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:

  • Jeffrey Helfand, DO (peer reviewer)
  • Warren Beckman (planning committee)
  • Kathleen Blake, PhD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)


  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

    TV-150-030922-08

    Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download